Loading
A phase 2 trial of pembrolizumab, carboplatin, pemetrexed and nab-paclitaxel in lung cancer, run by Kobe Minimally Invasive Cancer Center, not yet recruiting.
Pembrolizumab + Platinum Doublets Without Radiation for Programmed Death-ligand 1 (PD-L1) ≥50% Locally Advanced NSCLC is a phase 2, interventional study registered as NCT04153734 by Kobe Minimally Invasive Cancer Center, with a registry enrolment figure of 21 participants, started 2019-12-01 and due to reach its primary completion in 2021-11-30. Interventions recorded: Pembrolizumab; Cis Platinum; Carboplatin; Pemetrexed; nab paclitaxel. Conditions listed: Locally Advanced Non-small Cell Lung Cancer. Primary outcome: 2-year PFS rate. Lung eligibility wording from the registry: "Histologically confirmed NSCLC". No results are recorded here; the registry entry is the source.
Shares Nab-paclitaxel, Pemetrexed, Lung cancer trials open today (registry snapshot), Platinum agents and the tag lung-deep-dive.
Shares Pemetrexed, Lung cancer trials open today (registry snapshot), Platinum agents, Carboplatin and the tag lung-deep-dive.
Shares Nab-paclitaxel, Pemetrexed, Lung cancer trials open today (registry snapshot), Platinum agents and the tag lung-deep-dive.
Shares Pemetrexed, Lung cancer trials open today (registry snapshot), Platinum agents, Carboplatin and the tag lung-deep-dive.
Shares Pemetrexed, Lung cancer trials open today (registry snapshot), Platinum agents, Carboplatin and the tag lung-deep-dive.
Shares Nab-paclitaxel, Lung cancer trials open today (registry snapshot), Platinum agents, Carboplatin and the tag lung-deep-dive.
Shares Nab-paclitaxel, Lung cancer trials open today (registry snapshot), Platinum agents, Carboplatin and the tag lung-deep-dive.
Shares Pemetrexed, Lung cancer trials open today (registry snapshot), Platinum agents, Carboplatin and the tag lung-deep-dive.